{
    "nctId": "NCT05078190",
    "briefTitle": "Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer",
    "officialTitle": "Cardiotoxicity of Cancer Therapy 2: Mechanisms, Predictors, and Social Determinants of Health in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Change in Left Ventricular Ejection Fraction (LVEF)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women older than 18 years of age\n* Breast cancer with treatment plan that includes doxorubicin and/or trastuzumab\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy at enrollment\n* Inability or unwillingness to provide consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}